CardioScore was developed thanks to more than ten years of Genome Wide Association Studies (GWAS) aiming to understand the polygenic components of coronary artery disease (CAD).
Using large datasets consisting of hundreds of thousands of people was possible to identify more than 6 Million genetic variants that combined predict CAD risk.
The predictive power of CardioScore has been validated in more than 400.000 participants of the UK Biobank, showing the highest C-index when compared with the traditional risk factors.
CardioScore consists in the genotyping of 750.000 genetic variants distributed across the entire genome and the subsequent imputation of additional 6 Million genetic variants. Genetic variants undergo a stringent quality control pipeline and are finally used to compute the Polygenic Risk Score.